Wall Street brokerages expect Novavax, Inc. (NASDAQ:NVAX) to report ($0.15) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Novavax’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.14). Novavax posted earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The business is scheduled to announce its next quarterly earnings results on Monday, February 26th.

According to Zacks, analysts expect that Novavax will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.60). For the next year, analysts anticipate that the business will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.83) to ($0.50). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Novavax.

Several research firms recently commented on NVAX. B. Riley set a $10.00 price objective on Novavax and gave the company a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services increased their price objective on Novavax to $2.50 and gave the company a “buy” rating in a research note on Thursday, January 11th. S&P Equity Research reduced their price objective on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective on shares of Novavax in a research note on Wednesday, November 8th. Finally, Citigroup downgraded Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $2.64.

Several institutional investors and hedge funds have recently modified their holdings of the business. Teachers Advisors LLC increased its stake in shares of Novavax by 17.2% in the 4th quarter. Teachers Advisors LLC now owns 583,645 shares of the biopharmaceutical company’s stock worth $724,000 after acquiring an additional 85,611 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Novavax by 8.3% in the 4th quarter. California State Teachers Retirement System now owns 492,492 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 37,793 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Novavax in the 4th quarter worth $215,000. Deutsche Bank AG increased its stake in shares of Novavax by 6.3% in the 4th quarter. Deutsche Bank AG now owns 2,567,169 shares of the biopharmaceutical company’s stock worth $3,182,000 after acquiring an additional 152,974 shares during the last quarter. Finally, Rock Springs Capital Management LP increased its stake in shares of Novavax by 143.9% in the 4th quarter. Rock Springs Capital Management LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 1,180,000 shares during the last quarter. 35.71% of the stock is owned by institutional investors and hedge funds.

Novavax (NVAX) opened at $2.03 on Thursday. Novavax has a 52 week low of $0.73 and a 52 week high of $2.32. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28. The company has a market capitalization of $636.64, a price-to-earnings ratio of -2.99 and a beta of 2.68.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Novavax, Inc. (NVAX) to Announce -$0.15 Earnings Per Share” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/15/zacks-brokerages-anticipate-novavax-inc-nvax-to-announce-0-15-earnings-per-share.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.